Style | Citing Format |
---|---|
MLA | Rezaeizadeh H, et al.. "Effect of Ms14® on Physical Activity of Multiple Sclerosis Patients: A Randomized Triple-Blind Placebo-Controlled Clinical Trial." Multiple Sclerosis and Related Disorders, vol. 69, no. , 2023, pp. -. |
APA | Rezaeizadeh H, Gharegozli K, Nabavi SM, Shayegannejad V, Ghaffarpoor M, Daneshfard B, Cordato D, Naseri M (2023). Effect of Ms14® on Physical Activity of Multiple Sclerosis Patients: A Randomized Triple-Blind Placebo-Controlled Clinical Trial. Multiple Sclerosis and Related Disorders, 69(), -. |
Chicago | Rezaeizadeh H, Gharegozli K, Nabavi SM, Shayegannejad V, Ghaffarpoor M, Daneshfard B, Cordato D, Naseri M. "Effect of Ms14® on Physical Activity of Multiple Sclerosis Patients: A Randomized Triple-Blind Placebo-Controlled Clinical Trial." Multiple Sclerosis and Related Disorders 69, no. (2023): -. |
Harvard | Rezaeizadeh H et al. (2023) 'Effect of Ms14® on Physical Activity of Multiple Sclerosis Patients: A Randomized Triple-Blind Placebo-Controlled Clinical Trial', Multiple Sclerosis and Related Disorders, 69(), pp. -. |
Vancouver | Rezaeizadeh H, Gharegozli K, Nabavi SM, Shayegannejad V, Ghaffarpoor M, Daneshfard B, et al.. Effect of Ms14® on Physical Activity of Multiple Sclerosis Patients: A Randomized Triple-Blind Placebo-Controlled Clinical Trial. Multiple Sclerosis and Related Disorders. 2023;69():-. |
BibTex | @article{ author = {Rezaeizadeh H and Gharegozli K and Nabavi SM and Shayegannejad V and Ghaffarpoor M and Daneshfard B and Cordato D and Naseri M}, title = {Effect of Ms14® on Physical Activity of Multiple Sclerosis Patients: A Randomized Triple-Blind Placebo-Controlled Clinical Trial}, journal = {Multiple Sclerosis and Related Disorders}, volume = {69}, number = {}, pages = {-}, year = {2023} } |
RIS | TY - JOUR AU - Rezaeizadeh H AU - Gharegozli K AU - Nabavi SM AU - Shayegannejad V AU - Ghaffarpoor M AU - Daneshfard B AU - Cordato D AU - Naseri M TI - Effect of Ms14® on Physical Activity of Multiple Sclerosis Patients: A Randomized Triple-Blind Placebo-Controlled Clinical Trial JO - Multiple Sclerosis and Related Disorders VL - 69 IS - SP - EP - PY - 2023 ER - |